Anyone Testing Their GlycA?

[RobTuck]

Because I believe systemic inflammation underlies many destructive processes related to aging, and because it now appears that GlycA aggregates concentration and glycosylation/branching changes across multiple proteins, GlycA might serve as a composite readout of chronic, systemic inflammatory tone.

Analytically GlycA is very stable (unlike hsCRP or even IL-6) even though it correlates with hsCRP, fibrinogen, IL-6, etc. GlycA is said to track cardiometabolic risk, incident CVD, infection risk, and all-cause mortality, often independently of hsCRP. Because long-term stability of GlycA is better than hsCRP, it is optimally useful for serial monitoring of low-grade inflammation. In one pooled data study, GlycA related more strongly to MI, whereas hsCRP related more to ischemic stroke, suggesting a partially distinct biology.

With this in mind, I decided to test my GlycA for the first time. Having recently tested my hsCRP and Il-6 with the results of 0.35 and <2.5, respectively, I was expecting or at least hoping for a low test result. I was surprised to receive a report of 378, which is within the average range but not optimal and considerably discordant with my consistent CRRP and IL-6 metrics.

GPT-5.0 Pro suggested that this discordance is not rare and suggested I look for subtle chronic processes such as neutrophil activity, or metabolic, oral, or renal inflammation. My neutrophil count is in the middle of the normal range but my lymphocytes are toward the low end of the normal range, so there could be something there. I’ll begin looking around for other issues to see what I can identify but I thought it worth sharing in case others have or plan on assessing their GlycA.

Below is GPT’s analysis of typical metrics but I have not yet validated them. From some tables I consulted, the GlycA metric appears to be nonlinear with respect to risk.

Population Reference (healthy donors) ~288–518 µmol/L overall:
Men 273–487
Women 299–522
Mean Men ~370 µmol/L
Mean Women ~395 µmol/L

[RapAdmin]

More information:

GlycA: A Biomarker of Chronic Inflammation | Precision Health Reports

[RobTuck]

Another practical advantage is that GlycA is easily and inexpensively added to the routine in a NMR lipid profile. It is part of the MVX and one of two metrics that make up the inflammation subscale. A practical counter is that hsCRP is not as unstable as some think, especially if you rule out situations in which a spike would be expected (vaccinations, severe cold, post exercise, etc.). Looking back over a decade’s worth of annual hsCRP tests, the range is quite constrained in both distributional and functional terms (if not arithmetical): 0.2-0.6 mg/L.

One note of caution: norm tables are thin for those above 75 years of age. The means and distribution goes up but attaching clinical significance to scores is less well supported and a U-shaped healthy-benefit curve is a yet-to-be-discovered possibility for those of advanced age. For that matter, there could be such a thing as a too-low hsCRP for a healthy, active 80 year-old.

[qBx123Yk]

Were you able to improve your GlycA values?

[RobTuck]

I am not far enough along to be able to answer that. I will be testing next month and will be able to compare to my first score one year ago. Mechanistically, most GlycA values above a certain level should be improvable. I just asked GPT to weigh in on the distribution statistics and found some interesting additional information, one strand of which contradicts the data I have which shows a slight increase with age.

================
The evidence is more interesting than the usual “inflammaging → GlycA rises with age” story would suggest. In metabolically/clinically healthy humans, GlycA appears to be remarkably age-stable. The apparent increase with age seen in general-population datasets seems to be driven substantially by the accumulation of adiposity, metabolic dysfunction, renal impairment, frailty, and occult disease rather than chronological age itself.

1. What does the GlycA distribution look like?

For the Vantera/Labcorp-type GlycA assay, the best clean reference-distribution study remains the analytical-validation cohort of 450 apparently healthy adults aged 18–84 years.

Statistic	All	Men	Women
n	450	158	292
Mean	386	370	395
SD	60	57	60
2.5th percentile	288	273	299
25th percentile	346	340	350
Median	379	366	388
75th percentile	420	394	434
97.5th percentile	518	487	522
Observed range	245–605	245–605	269–599

All values are μmol/L.

The distribution is therefore fairly compact with modest positive skew:

• CV ≈ 60/386 ≈ 15.5%
• IQR = 74 μmol/L
• mean > median
• upper tail extends farther above the median than the lower tail extends below it.

It is much less dramatically right-skewed than hsCRP.

An important interpretive point is that Labcorp now reports a medical decision threshold of 400 μmol/L: <400 low; ≥400 high. That should not be mistaken for a statistical reference limit. In the healthy reference population, 400 lies only modestly above the median—roughly around the lower-to-mid 60th percentile by interpolation—not anywhere near the 95th percentile. So:

400 μmol/L is a risk-stratification cutoff, not an “abnormal population value” cutoff. That distinction matters considerably.

2. Large epidemiologic cohorts give broadly similar distributions

For example, in PREVEND, n=5,526, mean age 53.6 years, GlycA averaged:

352 ± 62 μmol/L.

In the Women’s Health Study, involving nearly 27,500 initially healthy women, the quartiles were:

• Q1: ≤326
• Q2: 327–369
• Q3: 370–416
• Q4: >416 μmol/L.

Median age was about 53 years. Those numbers are strikingly consistent with the analytical reference dataset, allowing for cohort selection, sex, specimen type and assay calibration. Thus I would characterize ordinary Vantera GlycA approximately as:

GlycA	Population interpretation
<300	unusually low
300–340	low
340–380	lower-middle
380–420	upper-middle
420–500	elevated population tail
>500	distinctly unusual in a healthy population

---

3. Does healthy aging itself increase GlycA?

Here the answer increasingly looks like no—or at most very slightly.

A particularly pertinent 2025 study deliberately constructed healthy cohorts to answer almost exactly this question. Lodge et al. studied healthy Australian and Spanish adults aged 20–70, stratifying them by decade:

20–29
30–39
40–49
50–59
60–70.

They found no significant effect of age on GlycA. Even more interestingly, among healthy men: > men aged 30–39 actually had higher GlycA than men aged 60–69. There was no significant age progression among women. Thus there was certainly no monotonic 30 → 40 → 50 → 60 → 70 “inflammaging” trajectory. That finding is particularly valuable because BMI strongly influenced glycoprotein inflammatory signals in their broader free-living population.

In other words: Age and the metabolic phenotype that commonly accompanies age are separable variables.

---

4. We now have an unusually informative longitudinal experiment above age 70

A Norwegian study followed 133 relatively healthy, community-dwelling older adults for eight years. Median age:

73 → 80 years.

Frailty clearly increased:

• frailty index: 0.11 → 0.20
• formally frail: 3% → 33%.

Yet Nightingale glycoprotein acetyls went: 0.86 ± 0.11 → 0.84 ± 0.10 mmol/L and the decline was statistically significant, p=0.002. That is a remarkable result for the question you are asking. Eight years of chronological aging from the early 70s into approximately age 80 did not increase GlycA at all. It decreased slightly. There is considerable survivor-selection here: those returning at follow-up were healthier than the original cohort, and medication use increased. The authors emphasize both issues. Nevertheless, the experiment effectively falsifies the strong hypothesis: > GlycA must rise progressively as a direct consequence of human aging. It clearly does not.

---

5. Why, then, do very large datasets say GlycA is an “aging biomarker”?

Because biological aging ≠ chronological aging. UK Biobank analyses involving >100,000 and in some cases ~250,000 subjects identify GlycA as one of the metabolites associated with chronological age, frailty and mortality. In one recent analysis GlycA had the strongest mortality association among the selected NMR biomarkers:

HR ≈1.25 per SD higher GlycA.

And GlycA was positively associated with 43 different frailty deficits; odds ratios were approximately:

• pre-frail: 1.31
• frail: 1.63

per standardized GlycA increment. This seems contradictory only if one treats chronological aging and biological deterioration as synonymous. A better causal picture is:

Age
↓
increasing variance in adiposity, visceral fat, insulin resistance, renal function, infection burden, periodontal disease, vascular disease, clonal hematopoiesis, pulmonary disease, etc.
↓
hepatic acute-phase response / altered glycoprotein production and glycosylation
↓
higher GlycA

rather than:

Age → GlycA

as a strong direct relationship.

PREVEND illustrates this confounding beautifully. Subjects in higher GlycA quartiles were older, but they also had higher BMI, BP, glucose, triglycerides, hsCRP and albuminuria; lower HDL and eGFR; and more hypertension, CVD, cancer and diabetes. Age is embedded in a whole cluster of deteriorating phenotypes.

---

6. GlycA may therefore be closer to a “healthspan deviation” marker than an aging marker

This is the interpretation I find most defensible. Consider three biomarkers conceptually:

Marker	Relationship with chronological aging
IL-6	tends to rise substantially
hsCRP	tends to rise, but highly episodic and disease/adiposity dependent
GlycA	surprisingly weak age dependence in healthy people

GlycA’s great advantage is that it integrates several relatively abundant acute-phase glycoproteins—principally α1-acid glycoprotein, haptoglobin, α1-antitrypsin and related glycoproteins—rather than measuring one rapidly responding cytokine or CRP molecule. Labcorp consequently notes lower intra-individual variability than hsCRP. Consequently, GlycA appears to behave more like a measure of the persistent inflammatory-metabolic state than an acute inflammatory snapshot. That leads to a useful distinction:

GlycA≈f(chronic inflammatory burden)

rather than

GlycA≈f(chronological age)

although inflammatory burden tends to increase with age in an unselected population.

---

My synthesis

The evidence now supports a fairly strong conclusion:

From middle age through approximately age 70, there is little evidence that GlycA needs any age correction in genuinely healthy humans. Even from the early 70s to about 80, limited longitudinal evidence shows no obligatory increase.

The higher GlycA distribution seen among older adults in epidemiological cohorts therefore appears to reflect primarily heterogeneity in biological aging and accumulated pathology, rather than a normal age-dependent upward resetting of GlycA.

That makes GlycA arguably more interesting in an older healthy individual, not less: unlike several inflammatory markers, one probably should not automatically discount a higher value as “normal for age.”

There is another layer worth examining: conditional GlycA distributions after controlling for BMI/waist, insulin resistance, eGFR, smoking, hsCRP and prevalent disease. My suspicion is that doing this would flatten the apparent age coefficient almost completely and might give us a much more meaningful “healthy-aging percentile” against which to interpret an individual GlycA measurement.